Side effects on muscles and nerves from MEK inhibitor drugs
Part of Bones, joints & muscles, Brain & nervous system, Immune system & allergy clinical trials.
This study reviews cases of muscle and nerve problems caused by MEK inhibitor drugs, which are used to treat certain cancers. The goal is to better understand these side effects so doctors can manage them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had muscle or nerve problems while taking a MEK inhibitor drug (alone or with other treatments).
- You are over 18 years old.
- You agree to let the researchers use your medical information for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for people with generalized myasthenia gravis (a condition causing muscle weakness) that hasn't improved with standard medications. The treatment, called blinatumomab, aims to reduce weakness by targeting certain immune cells.
This trial tests a targeted drug (MEK inhibitor) to treat thickened heart muscle caused by a group of genetic conditions called RASopathies. It may help improve heart function in people with hypertrophic cardiomyopathy.
This trial tests an experimental oral medication called NMD670 for people with myasthenia gravis (MG). It aims to see if the drug is safe and if it helps improve muscle strength and daily function.
This study tests an experimental treatment made from mitochondria (the energy centers of cells) for people with polymyositis or dermatomyositis that hasn't improved with standard treatments. It aims to see if the treatment is safe and can help reduce muscle weakness and other symptoms.
This study tests a new medicine for babies with a genetic condition that causes a thickened heart muscle. The medicine may help improve heart function in infants who are very sick and need hospital care.
This study tests a new medicine called UX016 for people with GNE myopathy, a rare genetic muscle disease that causes weakness in the hands and legs. The trial aims to see if the medicine is safe and whether it can help improve muscle strength. It is the first time this medicine is being tested in humans.
Hear when a new Myositis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.